Fourth FDA/Alzheimer’s Disease Allies Meeting
ACT-AD, together with the Cure Alzheimer’s Fund and Leaders Engaged on Alzheimer’s Disease (LEAD), hosted an FDA/Alzheimer’s Disease Allies Meeting with senior representatives from the U.S. Food and Drug Administration (FDA), leading scientists, drug developers, and Alzheimer’s advocates to address critical issues affecting the development and review of new Alzheimer’s disease therapies. The presentations, panels, and open dialog during the workshop focused on phase II experiences in current drug development programs and the potential application of scientific insights to support decision-making by drug developers and regulators in order to bring new treatments to market.
More Upcoming Events
“If You Build It, Will They Come?” Strategies for Alzheimer’s Disease Clinical Trial Recruitment WebinarThe Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) Coalition for an educational webinar on clinical trial…